The well known women’s healthcare company TherapeuticsMD (NASDAQ:TXMD) made a key announcement last week but that did not quite seem to impress investors and the stock tanked by as much as 9% last week.
In this situation it might be a good idea for investors to perhaps figure out if the decline in the stock price could be an opportunity to get into the TherapeuticsMD stock. The company announce that it made Hugh O’Dowd its new President. O’Dowd was appointed as a replacement for John C.K. Milligan, who had been appointed the Chief Executive Officer of vitaCare Prescription Services, an arm of TherapeuticsMD.
O’Dowd is a highly experienced executive and has worked with a range of large as well as small pharmaceutical companies in a career spanning more than two decades. As a matter of fact, he had been employed by the pharmaceutical giant Novartis for more than twenty years.
Robert G. Finzio, who is the Chief Executive Officer of TherapeuticsMD, spoke about the appointment as well. He stated that O’Dowd is going to be involved in unlocking more value for the company’s shareholders. While the appointment did not get a positive welcome from shareholders, it remains to be seen if the stock can recover.
